- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01131676
BI 10773 (Empagliflozin) Händelseförsök med kardiovaskulärt utfall i typ 2-diabetes mellituspatienter (EMPA-REG OUTCOME).
En fas III, multicenter, internationell, randomiserad, parallell grupp, dubbelblind kardiovaskulär säkerhetsstudie av BI 10773 (10 mg och 25 mg administrerat oralt en gång dagligen) jämfört med vanlig vård hos patienter med typ 2 diabetes mellitus med ökad kardiovaskulär risk
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Buenos Aires, Argentina
- 1245.25.54012 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 1245.25.54001 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 1245.25.54006 Boehringer Ingelheim Investigational Site
-
Capital Federal, Argentina
- 1245.25.54013 Boehringer Ingelheim Investigational Site
-
Cordoba, Argentina
- 1245.25.54010 Boehringer Ingelheim Investigational Site
-
Cordoba, Argentina
- 1245.25.54011 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 1245.25.54002 Boehringer Ingelheim Investigational Site
-
Córdoba, Argentina
- 1245.25.54003 Boehringer Ingelheim Investigational Site
-
Parque Velez Sarfield, Argentina
- 1245.25.54005 Boehringer Ingelheim Investigational Site
-
Rosario, Argentina
- 1245.25.54008 Boehringer Ingelheim Investigational Site
-
Rosario, Argentina
- 1245.25.54009 Boehringer Ingelheim Investigational Site
-
-
-
-
Queensland
-
Herston, Queensland, Australien
- 1245.25.61003 Boehringer Ingelheim Investigational Site
-
-
South Australia
-
Ashford, South Australia, Australien
- 1245.25.61001 Boehringer Ingelheim Investigational Site
-
Fullarton, South Australia, Australien
- 1245.25.61002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bonheiden, Belgien
- 1245.25.32010 Boehringer Ingelheim Investigational Site
-
Brussel, Belgien
- 1245.25.32030 Boehringer Ingelheim Investigational Site
-
Bruxelles, Belgien
- 1245.25.32008 Boehringer Ingelheim Investigational Site
-
Bruxelles, Belgien
- 1245.25.32011 Boehringer Ingelheim Investigational Site
-
De Pinte, Belgien
- 1245.25.32003 Boehringer Ingelheim Investigational Site
-
Edegem, Belgien
- 1245.25.32002 Boehringer Ingelheim Investigational Site
-
Genk, Belgien
- 1245.25.32004 Boehringer Ingelheim Investigational Site
-
Halen, Belgien
- 1245.25.32029 Boehringer Ingelheim Investigational Site
-
Hasselt, Belgien
- 1245.25.32009 Boehringer Ingelheim Investigational Site
-
Huy, Belgien
- 1245.25.32007 Boehringer Ingelheim Investigational Site
-
La Louvière, Belgien
- 1245.25.32013 Boehringer Ingelheim Investigational Site
-
Leuven, Belgien
- 1245.25.32012 Boehringer Ingelheim Investigational Site
-
Liège, Belgien
- 1245.25.32001 Boehringer Ingelheim Investigational Site
-
Liège, Belgien
- 1245.25.32028 Boehringer Ingelheim Investigational Site
-
Massemen-Wetteren, Belgien
- 1245.25.32005 Boehringer Ingelheim Investigational Site
-
Oostham, Belgien
- 1245.25.32014 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Belo Horizonte, Brasilien
- 1245.25.55019 Boehringer Ingelheim Investigational Site
-
Belém, Brasilien
- 1245.25.55014 Boehringer Ingelheim Investigational Site
-
Boqueirão, Brasilien
- 1245.25.55007 Boehringer Ingelheim Investigational Site
-
Brasília, Brasilien
- 1245.25.55015 Boehringer Ingelheim Investigational Site
-
Campinas, Brasilien
- 1245.25.55027 Boehringer Ingelheim Investigational Site
-
Campinas, Brasilien
- 1245.25.55028 Boehringer Ingelheim Investigational Site
-
Curitiba, Brasilien
- 1245.25.55025 Boehringer Ingelheim Investigational Site
-
Fortaleza, Brasilien
- 1245.25.55026 Boehringer Ingelheim Investigational Site
-
Goiânia, Brasilien
- 1245.25.55009 Boehringer Ingelheim Investigational Site
-
Higienópolis, Brasilien
- 1245.25.55002 Boehringer Ingelheim Investigational Site
-
Marilia, Brasilien
- 1245.25.55017 Boehringer Ingelheim Investigational Site
-
Maringá, Brasilien
- 1245.25.55022 Boehringer Ingelheim Investigational Site
-
Porto Alegre, Brasilien
- 1245.25.55008 Boehringer Ingelheim Investigational Site
-
Porto Alegre, Brasilien
- 1245.25.55016 Boehringer Ingelheim Investigational Site
-
Porto Alegre, Brasilien
- 1245.25.55020 Boehringer Ingelheim Investigational Site
-
Ribeirão Preto, Brasilien
- 1245.25.55012 Boehringer Ingelheim Investigational Site
-
São José do Rio Preto, Brasilien
- 1245.25.55013 Boehringer Ingelheim Investigational Site
-
São Paulo, Brasilien
- 1245.25.55004 Boehringer Ingelheim Investigational Site
-
São Paulo, Brasilien
- 1245.25.55010 Boehringer Ingelheim Investigational Site
-
São Paulo, Brasilien
- 1245.25.55018 Boehringer Ingelheim Investigational Site
-
São Paulo, Brasilien
- 1245.25.55023 Boehringer Ingelheim Investigational Site
-
Vila Albuquerque, Brasilien
- 1245.25.55006 Boehringer Ingelheim Investigational Site
-
Vila Clementino, Brasilien
- 1245.25.55003 Boehringer Ingelheim Investigational Site
-
Vila Leopoldina, Brasilien
- 1245.25.55005 Boehringer Ingelheim Investigational Site
-
Villa Clementino, Brasilien
- 1245.25.55001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Armenia, Colombia
- 1245.25.57010 Boehringer Ingelheim Investigational Site
-
Barranquilla, Colombia
- 1245.25.57004 Boehringer Ingelheim Investigational Site
-
Bogotá, Colombia
- 1245.25.57001 Boehringer Ingelheim Investigational Site
-
Bogotá, Colombia
- 1245.25.57003 Boehringer Ingelheim Investigational Site
-
Bogotá, Colombia
- 1245.25.57011 Boehringer Ingelheim Investigational Site
-
Floridablanca, Colombia
- 1245.25.57006 Boehringer Ingelheim Investigational Site
-
Medellín, Colombia
- 1245.25.57009 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Frederiksberg, Danmark
- 1245.25.45006 Boehringer Ingelheim Investigational Site
-
Gentofte, Danmark
- 1245.25.45003 Boehringer Ingelheim Investigational Site
-
Helsingør, Danmark
- 1245.25.45007 Boehringer Ingelheim Investigational Site
-
København NV, Danmark
- 1245.25.45002 Boehringer Ingelheim Investigational Site
-
Randers NØ, Danmark
- 1245.25.45004 Boehringer Ingelheim Investigational Site
-
Slagelse, Danmark
- 1245.25.45005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Tallin, Estland
- 1245.25.37002 Boehringer Ingelheim Investigational Site
-
Tallin, Estland
- 1245.25.37005 Boehringer Ingelheim Investigational Site
-
Tallinn, Estland
- 1245.25.37003 Boehringer Ingelheim Investigational Site
-
Tartu, Estland
- 1245.25.37001 Boehringer Ingelheim Investigational Site
-
Tartu, Estland
- 1245.25.37004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Cavite City, Filippinerna
- 1245.25.63016 Boehringer Ingelheim Investigational Site
-
Cebu, Filippinerna
- 1245.25.63002 Boehringer Ingelheim Investigational Site
-
Davao, Filippinerna
- 1245.25.63003 Boehringer Ingelheim Investigational Site
-
Jaro Iloilo City, Filippinerna
- 1245.25.63020 Boehringer Ingelheim Investigational Site
-
Manila, Filippinerna
- 1245.25.63001 Boehringer Ingelheim Investigational Site
-
Manila, Filippinerna
- 1245.25.63004 Boehringer Ingelheim Investigational Site
-
Manila, Filippinerna
- 1245.25.63018 Boehringer Ingelheim Investigational Site
-
Marikina City, Filippinerna
- 1245.25.63009 Boehringer Ingelheim Investigational Site
-
Marikina City, Filippinerna
- 1245.25.63021 Boehringer Ingelheim Investigational Site
-
Tarlac, Filippinerna
- 1245.25.63019 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amiens, Frankrike
- 1245.25.33022 Boehringer Ingelheim Investigational Site
-
Angers, Frankrike
- 1245.25.33033 Boehringer Ingelheim Investigational Site
-
Angers, Frankrike
- 1245.25.33034 Boehringer Ingelheim Investigational Site
-
Bourg des cptes, Frankrike
- 1245.25.33030 Boehringer Ingelheim Investigational Site
-
Corbeil Essonnes, Frankrike
- 1245.25.33023 Boehringer Ingelheim Investigational Site
-
Derval, Frankrike
- 1245.25.33024 Boehringer Ingelheim Investigational Site
-
Equeurdreville Haineville, Frankrike
- 1245.25.33029 Boehringer Ingelheim Investigational Site
-
Fleury sur Orne, Frankrike
- 1245.25.33027 Boehringer Ingelheim Investigational Site
-
Grenoble, Frankrike
- 1245.25.33021 Boehringer Ingelheim Investigational Site
-
La Rochelle Cedex 1, Frankrike
- 1245.25.33003 Boehringer Ingelheim Investigational Site
-
Le Creusot, Frankrike
- 1245.25.33032 Boehringer Ingelheim Investigational Site
-
Narbonne Cedex, Frankrike
- 1245.25.33004 Boehringer Ingelheim Investigational Site
-
Pessac, Frankrike
- 1245.25.33047 Boehringer Ingelheim Investigational Site
-
Poitiers, Frankrike
- 1245.25.33046 Boehringer Ingelheim Investigational Site
-
Saint Priez en Jarez, Frankrike
- 1245.25.33025 Boehringer Ingelheim Investigational Site
-
Tours, Frankrike
- 1245.25.33035 Boehringer Ingelheim Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna
- 1245.25.10043 Boehringer Ingelheim Investigational Site
-
Birmingham, Alabama, Förenta staterna
- 1245.25.10121 Boehringer Ingelheim Investigational Site
-
Huntsville, Alabama, Förenta staterna
- 1245.25.10037 Boehringer Ingelheim Investigational Site
-
Mobile, Alabama, Förenta staterna
- 1245.25.10124 Boehringer Ingelheim Investigational Site
-
-
Alaska
-
Little Rock, Alaska, Förenta staterna
- 1245.25.10015 Boehringer Ingelheim Investigational Site
-
-
Arizona
-
Gilbert, Arizona, Förenta staterna
- 1245.25.10056 Boehringer Ingelheim Investigational Site
-
Peoria, Arizona, Förenta staterna
- 1245.25.10175 Boehringer Ingelheim Investigational Site
-
Phoenix, Arizona, Förenta staterna
- 1245.25.10072 Boehringer Ingelheim Investigational Site
-
-
Arkansas
-
Harrisburg, Arkansas, Förenta staterna
- 1245.25.10048 Boehringer Ingelheim Investigational Site
-
-
California
-
Anaheim, California, Förenta staterna
- 1245.25.10035 Boehringer Ingelheim Investigational Site
-
Encino, California, Förenta staterna
- 1245.25.10103 Boehringer Ingelheim Investigational Site
-
Fresno, California, Förenta staterna
- 1245.25.10158 Boehringer Ingelheim Investigational Site
-
Harbor City, California, Förenta staterna
- 1245.25.10126 Boehringer Ingelheim Investigational Site
-
Huntington Park, California, Förenta staterna
- 1245.25.10058 Boehringer Ingelheim Investigational Site
-
Lancaster, California, Förenta staterna
- 1245.25.10001 Boehringer Ingelheim Investigational Site
-
Los Angeles, California, Förenta staterna
- 1245.25.10102 Boehringer Ingelheim Investigational Site
-
Los Gatos, California, Förenta staterna
- 1245.25.10047 Boehringer Ingelheim Investigational Site
-
Palm Springs, California, Förenta staterna
- 1245.25.10118 Boehringer Ingelheim Investigational Site
-
Riverside, California, Förenta staterna
- 1245.25.10061 Boehringer Ingelheim Investigational Site
-
San Diego, California, Förenta staterna
- 1245.25.10040 Boehringer Ingelheim Investigational Site
-
San Diego, California, Förenta staterna
- 1245.25.10055 Boehringer Ingelheim Investigational Site
-
San Diego, California, Förenta staterna
- 1245.25.10193 Boehringer Ingelheim Investigational Site
-
Santa Rosa, California, Förenta staterna
- 1245.25.10027 Boehringer Ingelheim Investigational Site
-
Stockton, California, Förenta staterna
- 1245.25.10074 Boehringer Ingelheim Investigational Site
-
Valencia, California, Förenta staterna
- 1245.25.10083 Boehringer Ingelheim Investigational Site
-
-
Colorado
-
Colorado Springs, Colorado, Förenta staterna
- 1245.25.10144 Boehringer Ingelheim Investigational Site
-
Denver, Colorado, Förenta staterna
- 1245.25.10085 Boehringer Ingelheim Investigational Site
-
Denver, Colorado, Förenta staterna
- 1245.25.10153 Boehringer Ingelheim Investigational Site
-
-
Connecticut
-
Norwalk, Connecticut, Förenta staterna
- 1245.25.10066 Boehringer Ingelheim Investigational Site
-
Waterbury, Connecticut, Förenta staterna
- 1245.25.10038 Boehringer Ingelheim Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Förenta staterna
- 1245.25.10068 Boehringer Ingelheim Investigational Site
-
-
Florida
-
Bradenton, Florida, Förenta staterna
- 1245.25.10094 Boehringer Ingelheim Investigational Site
-
Brooksville, Florida, Förenta staterna
- 1245.25.10190 Boehringer Ingelheim Investigational Site
-
Clearwater, Florida, Förenta staterna
- 1245.25.10209 Boehringer Ingelheim Investigational Site
-
Cooper City, Florida, Förenta staterna
- 1245.25.10212 Boehringer Ingelheim Investigational Site
-
Delray Beach, Florida, Förenta staterna
- 1245.25.10200 Boehringer Ingelheim Investigational Site
-
Ft. Lauderdale, Florida, Förenta staterna
- 1245.25.10033 Boehringer Ingelheim Investigational Site
-
Hallandale Beach, Florida, Förenta staterna
- 1245.25.10202 Boehringer Ingelheim Investigational Site
-
Hialeah, Florida, Förenta staterna
- 1245.25.10062 Boehringer Ingelheim Investigational Site
-
Hialeah, Florida, Förenta staterna
- 1245.25.10063 Boehringer Ingelheim Investigational Site
-
Hialeah, Florida, Förenta staterna
- 1245.25.10157 Boehringer Ingelheim Investigational Site
-
Jacksonville, Florida, Förenta staterna
- 1245.25.10089 Boehringer Ingelheim Investigational Site
-
Longwood, Florida, Förenta staterna
- 1245.25.10019 Boehringer Ingelheim Investigational Site
-
Maitland, Florida, Förenta staterna
- 1245.25.10168 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Förenta staterna
- 1245.25.10018 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Förenta staterna
- 1245.25.10039 Boehringer Ingelheim Investigational Site
-
Miami, Florida, Förenta staterna
- 1245.25.10184 Boehringer Ingelheim Investigational Site
-
Orlando, Florida, Förenta staterna
- 1245.25.10123 Boehringer Ingelheim Investigational Site
-
Orlando, Florida, Förenta staterna
- 1245.25.10201 Boehringer Ingelheim Investigational Site
-
Pembroke Pines, Florida, Förenta staterna
- 1245.25.10025 Boehringer Ingelheim Investigational Site
-
Pembroke Pines, Florida, Förenta staterna
- 1245.25.10042 Boehringer Ingelheim Investigational Site
-
Port Charlotte, Florida, Förenta staterna
- 1245.25.10147 Boehringer Ingelheim Investigational Site
-
Saint Petersburg, Florida, Förenta staterna
- 1245.25.10198 Boehringer Ingelheim Investigational Site
-
Saint Petersburg, Florida, Förenta staterna
- 1245.25.10203 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Förenta staterna
- 1245.25.10104 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Förenta staterna
- 1245.25.10178 Boehringer Ingelheim Investigational Site
-
Tampa, Florida, Förenta staterna
- 1245.25.10211 Boehringer Ingelheim Investigational Site
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna
- 1245.25.10023 Boehringer Ingelheim Investigational Site
-
Columbus, Georgia, Förenta staterna
- 1245.25.10174 Boehringer Ingelheim Investigational Site
-
Riverdale, Georgia, Förenta staterna
- 1245.25.10141 Boehringer Ingelheim Investigational Site
-
Roswell, Georgia, Förenta staterna
- 1245.25.10067 Boehringer Ingelheim Investigational Site
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna
- 1245.25.10022 Boehringer Ingelheim Investigational Site
-
-
Idaho
-
Boise, Idaho, Förenta staterna
- 1245.25.10092 Boehringer Ingelheim Investigational Site
-
-
Illinois
-
Chicago, Illinois, Förenta staterna
- 1245.25.10097 Boehringer Ingelheim Investigational Site
-
-
Indiana
-
Evansville, Indiana, Förenta staterna
- 1245.25.10116 Boehringer Ingelheim Investigational Site
-
Valparaiso, Indiana, Förenta staterna
- 1245.25.10206 Boehringer Ingelheim Investigational Site
-
-
Kansas
-
Wichita, Kansas, Förenta staterna
- 1245.25.10021 Boehringer Ingelheim Investigational Site
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna
- 1245.25.10186 Boehringer Ingelheim Investigational Site
-
Louisville, Kentucky, Förenta staterna
- 1245.25.10109 Boehringer Ingelheim Investigational Site
-
Madisonville, Kentucky, Förenta staterna
- 1245.25.10006 Boehringer Ingelheim Investigational Site
-
Paducah, Kentucky, Förenta staterna
- 1245.25.10005 Boehringer Ingelheim Investigational Site
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna
- 1245.25.10020 Boehringer Ingelheim Investigational Site
-
-
Maine
-
Auburn, Maine, Förenta staterna
- 1245.25.10012 Boehringer Ingelheim Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna
- 1245.25.10041 Boehringer Ingelheim Investigational Site
-
Hyattsville, Maryland, Förenta staterna
- 1245.25.10134 Boehringer Ingelheim Investigational Site
-
Towson, Maryland, Förenta staterna
- 1245.25.10210 Boehringer Ingelheim Investigational Site
-
-
Massachusetts
-
Springfield, Massachusetts, Förenta staterna
- 1245.25.10064 Boehringer Ingelheim Investigational Site
-
Watertown, Massachusetts, Förenta staterna
- 1245.25.10051 Boehringer Ingelheim Investigational Site
-
-
Michigan
-
Dearborn, Michigan, Förenta staterna
- 1245.25.10071 Boehringer Ingelheim Investigational Site
-
Flint, Michigan, Förenta staterna
- 1245.25.10013 Boehringer Ingelheim Investigational Site
-
Petoskey, Michigan, Förenta staterna
- 1245.25.10107 Boehringer Ingelheim Investigational Site
-
-
Minnesota
-
Eagan, Minnesota, Förenta staterna
- 1245.25.10030 Boehringer Ingelheim Investigational Site
-
Minneapolis, Minnesota, Förenta staterna
- 1245.25.10028 Boehringer Ingelheim Investigational Site
-
-
Mississippi
-
Picayune, Mississippi, Förenta staterna
- 1245.25.10176 Boehringer Ingelheim Investigational Site
-
-
Missouri
-
Chesterfield, Missouri, Förenta staterna
- 1245.25.10011 Boehringer Ingelheim Investigational Site
-
Kansas City, Missouri, Förenta staterna
- 1245.25.10163 Boehringer Ingelheim Investigational Site
-
-
Montana
-
Great Falls, Montana, Förenta staterna
- 1245.25.10148 Boehringer Ingelheim Investigational Site
-
Great Falls, Montana, Förenta staterna
- 1245.25.10191 Boehringer Ingelheim Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna
- 1245.25.10034 Boehringer Ingelheim Investigational Site
-
-
New Jersey
-
Flemington, New Jersey, Förenta staterna
- 1245.25.10014 Boehringer Ingelheim Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna
- 1245.25.10145 Boehringer Ingelheim Investigational Site
-
Albuquerque, New Mexico, Förenta staterna
- 1245.25.10180 Boehringer Ingelheim Investigational Site
-
-
New York
-
Binghamton, New York, Förenta staterna
- 1245.25.10131 Boehringer Ingelheim Investigational Site
-
Rochester, New York, Förenta staterna
- 1245.25.10029 Boehringer Ingelheim Investigational Site
-
Smithtown, New York, Förenta staterna
- 1245.25.10142 Boehringer Ingelheim Investigational Site
-
Staten Island, New York, Förenta staterna
- 1245.25.10096 Boehringer Ingelheim Investigational Site
-
-
North Carolina
-
Burlington, North Carolina, Förenta staterna
- 1245.25.10196 Boehringer Ingelheim Investigational Site
-
Calabash, North Carolina, Förenta staterna
- 1245.25.10207 Boehringer Ingelheim Investigational Site
-
Durham, North Carolina, Förenta staterna
- 1245.25.10053 Boehringer Ingelheim Investigational Site
-
Greenville, North Carolina, Förenta staterna
- 1245.25.10010 Boehringer Ingelheim Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna
- 1245.25.10060 Boehringer Ingelheim Investigational Site
-
Cincinnati, Ohio, Förenta staterna
- 1245.25.10086 Boehringer Ingelheim Investigational Site
-
Dayton, Ohio, Förenta staterna
- 1245.25.10137 Boehringer Ingelheim Investigational Site
-
Delaware, Ohio, Förenta staterna
- 1245.25.10138 Boehringer Ingelheim Investigational Site
-
Kettering, Ohio, Förenta staterna
- 1245.25.10156 Boehringer Ingelheim Investigational Site
-
Marion, Ohio, Förenta staterna
- 1245.25.10091 Boehringer Ingelheim Investigational Site
-
Zanesville, Ohio, Förenta staterna
- 1245.25.10192 Boehringer Ingelheim Investigational Site
-
-
Oklahoma
-
Norman, Oklahoma, Förenta staterna
- 1245.25.10114 Boehringer Ingelheim Investigational Site
-
-
Oregon
-
Eugene, Oregon, Förenta staterna
- 1245.25.10082 Boehringer Ingelheim Investigational Site
-
-
Pennsylvania
-
Clairton, Pennsylvania, Förenta staterna
- 1245.25.10154 Boehringer Ingelheim Investigational Site
-
Clairton, Pennsylvania, Förenta staterna
- 1245.25.10173 Boehringer Ingelheim Investigational Site
-
Feasterville Trevose, Pennsylvania, Förenta staterna
- 1245.25.10052 Boehringer Ingelheim Investigational Site
-
Fleetwood, Pennsylvania, Förenta staterna
- 1245.25.10069 Boehringer Ingelheim Investigational Site
-
Greensburg, Pennsylvania, Förenta staterna
- 1245.25.10172 Boehringer Ingelheim Investigational Site
-
Indiana, Pennsylvania, Förenta staterna
- 1245.25.10050 Boehringer Ingelheim Investigational Site
-
Lansdale, Pennsylvania, Förenta staterna
- 1245.25.10009 Boehringer Ingelheim Investigational Site
-
Philadelphia, Pennsylvania, Förenta staterna
- 1245.25.10214 Boehringer Ingelheim Investigational Site
-
Pittsburgh, Pennsylvania, Förenta staterna
- 1245.25.10149 Boehringer Ingelheim Investigational Site
-
Pittsburgh, Pennsylvania, Förenta staterna
- 1245.25.10197 Boehringer Ingelheim Investigational Site
-
Scottdale, Pennsylvania, Förenta staterna
- 1245.25.10159 Boehringer Ingelheim Investigational Site
-
Tipton, Pennsylvania, Förenta staterna
- 1245.25.10162 Boehringer Ingelheim Investigational Site
-
Uniontown, Pennsylvania, Förenta staterna
- 1245.25.10146 Boehringer Ingelheim Investigational Site
-
Yardley, Pennsylvania, Förenta staterna
- 1245.25.10077 Boehringer Ingelheim Investigational Site
-
-
South Carolina
-
Anderson, South Carolina, Förenta staterna
- 1245.25.10070 Boehringer Ingelheim Investigational Site
-
Charleston, South Carolina, Förenta staterna
- 1245.25.10044 Boehringer Ingelheim Investigational Site
-
Greer, South Carolina, Förenta staterna
- 1245.25.10002 Boehringer Ingelheim Investigational Site
-
Hodges, South Carolina, Förenta staterna
- 1245.25.10132 Boehringer Ingelheim Investigational Site
-
Mt. Pleasant, South Carolina, Förenta staterna
- 1245.25.10140 Boehringer Ingelheim Investigational Site
-
Myrtle Beach, South Carolina, Förenta staterna
- 1245.25.10065 Boehringer Ingelheim Investigational Site
-
Myrtle Beach, South Carolina, Förenta staterna
- 1245.25.10127 Boehringer Ingelheim Investigational Site
-
North Myrtle Beach, South Carolina, Förenta staterna
- 1245.25.10170 Boehringer Ingelheim Investigational Site
-
Spartanburg, South Carolina, Förenta staterna
- 1245.25.10129 Boehringer Ingelheim Investigational Site
-
Union, South Carolina, Förenta staterna
- 1245.25.10171 Boehringer Ingelheim Investigational Site
-
-
Tennessee
-
Bristol, Tennessee, Förenta staterna
- 1245.25.10054 Boehringer Ingelheim Investigational Site
-
Chattanooga, Tennessee, Förenta staterna
- 1245.25.10036 Boehringer Ingelheim Investigational Site
-
Chattanooga, Tennessee, Förenta staterna
- 1245.25.10057 Boehringer Ingelheim Investigational Site
-
Kingsport, Tennessee, Förenta staterna
- 1245.25.10046 Boehringer Ingelheim Investigational Site
-
Memphis, Tennessee, Förenta staterna
- 1245.25.10143 Boehringer Ingelheim Investigational Site
-
-
Texas
-
Corpus Christi, Texas, Förenta staterna
- 1245.25.10075 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, Förenta staterna
- 1245.25.10007 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, Förenta staterna
- 1245.25.10026 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, Förenta staterna
- 1245.25.10100 Boehringer Ingelheim Investigational Site
-
Dallas, Texas, Förenta staterna
- 1245.25.10165 Boehringer Ingelheim Investigational Site
-
Fort Worth, Texas, Förenta staterna
- 1245.25.10169 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Förenta staterna
- 1245.25.10003 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Förenta staterna
- 1245.25.10125 Boehringer Ingelheim Investigational Site
-
Houston, Texas, Förenta staterna
- 1245.25.10189 Boehringer Ingelheim Investigational Site
-
Lubbock, Texas, Förenta staterna
- 1245.25.10119 Boehringer Ingelheim Investigational Site
-
New Braunfels, Texas, Förenta staterna
- 1245.25.10078 Boehringer Ingelheim Investigational Site
-
Odessa, Texas, Förenta staterna
- 1245.25.10076 Boehringer Ingelheim Investigational Site
-
Pearland, Texas, Förenta staterna
- 1245.25.10133 Boehringer Ingelheim Investigational Site
-
Plano, Texas, Förenta staterna
- 1245.25.10160 Boehringer Ingelheim Investigational Site
-
Richardson, Texas, Förenta staterna
- 1245.25.10177 Boehringer Ingelheim Investigational Site
-
San Antonio, Texas, Förenta staterna
- 1245.25.10049 Boehringer Ingelheim Investigational Site
-
San Antonio, Texas, Förenta staterna
- 1245.25.10161 Boehringer Ingelheim Investigational Site
-
-
Utah
-
Bountiful, Utah, Förenta staterna
- 1245.25.10185 Boehringer Ingelheim Investigational Site
-
Draper, Utah, Förenta staterna
- 1245.25.10155 Boehringer Ingelheim Investigational Site
-
Midvale, Utah, Förenta staterna
- 1245.25.10079 Boehringer Ingelheim Investigational Site
-
Salt Lake City, Utah, Förenta staterna
- 1245.25.10080 Boehringer Ingelheim Investigational Site
-
South Ogden, Utah, Förenta staterna
- 1245.25.10087 Boehringer Ingelheim Investigational Site
-
-
Virginia
-
Burke, Virginia, Förenta staterna
- 1245.25.10218 Boehringer Ingelheim Investigational Site
-
Norfolk, Virginia, Förenta staterna
- 1245.25.10004 Boehringer Ingelheim Investigational Site
-
South Chesterfield, Virginia, Förenta staterna
- 1245.25.10111 Boehringer Ingelheim Investigational Site
-
-
Washington
-
Spokane, Washington, Förenta staterna
- 1245.25.10115 Boehringer Ingelheim Investigational Site
-
Spokane, Washington, Förenta staterna
- 1245.25.10216 Boehringer Ingelheim Investigational Site
-
Tacoma, Washington, Förenta staterna
- 1245.25.10017 Boehringer Ingelheim Investigational Site
-
Walla Walla, Washington, Förenta staterna
- 1245.25.10016 Boehringer Ingelheim Investigational Site
-
-
West Virginia
-
Charleston, West Virginia, Förenta staterna
- 1245.25.10187 Boehringer Ingelheim Investigational Site
-
Morgantown, West Virginia, Förenta staterna
- 1245.25.10182 Boehringer Ingelheim Investigational Site
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna
- 1245.25.10098 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Batumi, Georgien
- 1245.25.99001 Boehringer Ingelheim Investigational Site
-
Kutaisi, Georgien
- 1245.25.99003 Boehringer Ingelheim Investigational Site
-
Tbilisi, Georgien
- 1245.25.99002 Boehringer Ingelheim Investigational Site
-
Tbilisi, Georgien
- 1245.25.99004 Boehringer Ingelheim Investigational Site
-
Tbilisi, Georgien
- 1245.25.99005 Boehringer Ingelheim Investigational Site
-
Tbilisi, Georgien
- 1245.25.99006 Boehringer Ingelheim Investigational Site
-
Tbilisi, Georgien
- 1245.25.99007 Boehringer Ingelheim Investigational Site
-
Tbilisi, Georgien
- 1245.25.99008 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Athens, Grekland
- 1245.25.30002 Boehringer Ingelheim Investigational Site
-
Athens, Grekland
- 1245.25.30003 Boehringer Ingelheim Investigational Site
-
Athens, Grekland
- 1245.25.30004 Boehringer Ingelheim Investigational Site
-
Athens, Grekland
- 1245.25.30007 Boehringer Ingelheim Investigational Site
-
Larissa, Grekland
- 1245.25.30005 Boehringer Ingelheim Investigational Site
-
Nikaia, Grekland
- 1245.25.30001 Boehringer Ingelheim Investigational Site
-
Thessaloniki, Grekland
- 1245.25.30006 Boehringer Ingelheim Investigational Site
-
Thessaloniki, Grekland
- 1245.25.30008 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Hong Kong, Hong Kong
- 1245.25.85201 Boehringer Ingelheim Investigational Site
-
Hong Kong, Hong Kong
- 1245.25.85205 Boehringer Ingelheim Investigational Site
-
Hong Kong, Hong Kong
- 1245.25.85207 Boehringer Ingelheim Investigational Site
-
Hong Kong, Hong Kong
- 1245.25.85208 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Ahmedabad, Indien
- 1245.25.91307 Boehringer Ingelheim Investigational Site
-
Bangalore, Indien
- 1245.25.91302 Boehringer Ingelheim Investigational Site
-
Bangalore, Indien
- 1245.25.91317 Boehringer Ingelheim Investigational Site
-
Bangalore, Indien
- 1245.25.91319 Boehringer Ingelheim Investigational Site
-
Bangalore, Indien
- 1245.25.91320 Boehringer Ingelheim Investigational Site
-
Chennai, Indien
- 1245.25.91303 Boehringer Ingelheim Investigational Site
-
Cochin, Indien
- 1245.25.91315 Boehringer Ingelheim Investigational Site
-
Hyderabad, Indien
- 1245.25.91311 Boehringer Ingelheim Investigational Site
-
Indore, Indien
- 1245.25.91318 Boehringer Ingelheim Investigational Site
-
Jaipur, Indien
- 1245.25.91305 Boehringer Ingelheim Investigational Site
-
Jalandhar, Indien
- 1245.25.91309 Boehringer Ingelheim Investigational Site
-
Nagpur, Indien
- 1245.25.91313 Boehringer Ingelheim Investigational Site
-
Nagpur, Indien
- 1245.25.91324 Boehringer Ingelheim Investigational Site
-
Nashik, Maharashtra, Indien
- 1245.25.91301 Boehringer Ingelheim Investigational Site
-
Pune, Indien
- 1245.25.91308 Boehringer Ingelheim Investigational Site
-
Secunderabad, Indien
- 1245.25.91316 Boehringer Ingelheim Investigational Site
-
Varanasi, Indien
- 1245.25.91321 Boehringer Ingelheim Investigational Site
-
Vijaywada, Indien
- 1245.25.91314 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Denpasar, Bali, Indonesien
- 1245.25.62006 Boehringer Ingelheim Investigational Site
-
Depok, Indonesien
- 1245.25.62009 Boehringer Ingelheim Investigational Site
-
Jakarta, Indonesien
- 1245.25.62002 Boehringer Ingelheim Investigational Site
-
Jakarta, Indonesien
- 1245.25.62008 Boehringer Ingelheim Investigational Site
-
Jakarta, Indonesien
- 1245.25.62010 Boehringer Ingelheim Investigational Site
-
Malang, Indonesien
- 1245.25.62004 Boehringer Ingelheim Investigational Site
-
Surabaya, Indonesien
- 1245.25.62003 Boehringer Ingelheim Investigational Site
-
Yogyakarta, Indonesien
- 1245.25.62001 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Afula, Israel
- 1245.25.97003 Boehringer Ingelheim Investigational Site
-
Hadera, Israel
- 1245.25.97006 Boehringer Ingelheim Investigational Site
-
Haifa, Israel
- 1245.25.97008 Boehringer Ingelheim Investigational Site
-
Holon, Israel
- 1245.25.97009 Boehringer Ingelheim Investigational Site
-
Nahariya, Israel
- 1245.25.97005 Boehringer Ingelheim Investigational Site
-
Safed, Israel
- 1245.25.97001 Boehringer Ingelheim Investigational Site
-
Zerifin, Israel
- 1245.25.97002 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bologna, Italien
- 1245.25.39007 Boehringer Ingelheim Investigational Site
-
Campobasso, Italien
- 1245.25.39002 Boehringer Ingelheim Investigational Site
-
Catanzaro, Italien
- 1245.25.39008 Boehringer Ingelheim Investigational Site
-
Chieti, Italien
- 1245.25.39010 Boehringer Ingelheim Investigational Site
-
Ferrara, Italien
- 1245.25.39024 Boehringer Ingelheim Investigational Site
-
Firenze, Italien
- 1245.25.39009 Boehringer Ingelheim Investigational Site
-
Foggia, Italien
- 1245.25.39005 Boehringer Ingelheim Investigational Site
-
Napoli, Italien
- 1245.25.39004 Boehringer Ingelheim Investigational Site
-
Padova, Italien
- 1245.25.39006 Boehringer Ingelheim Investigational Site
-
Pisa, Italien
- 1245.25.39001 Boehringer Ingelheim Investigational Site
-
Roma, Italien
- 1245.25.39003 Boehringer Ingelheim Investigational Site
-
Roma, Italien
- 1245.25.39011 Boehringer Ingelheim Investigational Site
-
Roma, Italien
- 1245.25.39012 Boehringer Ingelheim Investigational Site
-
Roma, Italien
- 1245.25.39014 Boehringer Ingelheim Investigational Site
-
Venezia, Italien
- 1245.25.39013 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Chuo-ku, tokyo, Japan
- 1245.25.81008 Boehringer Ingelheim Investigational Site
-
Gifushi, Gifu, Japan
- 1245.25.81010 Boehringer Ingelheim Investigational Site
-
Hanyushi, Saitama, Japan
- 1245.25.81002 Boehringer Ingelheim Investigational Site
-
Kamigyo-ku, Kyotoshi, Kyoto, Japan
- 1245.25.81013 Boehringer Ingelheim Investigational Site
-
Kishiwadashi. Osaka, Japan
- 1245.25.81003 Boehringer Ingelheim Investigational Site
-
Kita-ku, Nagoyashi, Aichi, Japan
- 1245.25.81012 Boehringer Ingelheim Investigational Site
-
Kumamoto-shi, Kumamoto, Japan
- 1245.25.81014 Boehringer Ingelheim Investigational Site
-
Matsudoshi, Chiba, Japan
- 1245.25.81001 Boehringer Ingelheim Investigational Site
-
Mitoshi, Ibaraki, Japan
- 1245.25.81006 Boehringer Ingelheim Investigational Site
-
Nishi-ku, Sapporoshi, Hokkaido, Japan
- 1245.25.81005 Boehringer Ingelheim Investigational Site
-
Nodashi, Chiba, Japan
- 1245.25.81007 Boehringer Ingelheim Investigational Site
-
Shimajiri-gun,Okinawa, Japan
- 1245.25.81004 Boehringer Ingelheim Investigational Site
-
Toyamashi, Toyama, Japan
- 1245.25.81009 Boehringer Ingelheim Investigational Site
-
Toyoakeshi, Aichi, Japan
- 1245.25.81015 Boehringer Ingelheim Investigational Site
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
- 1245.25.20047 Boehringer Ingelheim Investigational Site
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada
- 1245.25.20048 Boehringer Ingelheim Investigational Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada
- 1245.25.20026 Boehringer Ingelheim Investigational Site
-
-
Ontario
-
Brampton, Ontario, Kanada
- 1245.25.20045 Boehringer Ingelheim Investigational Site
-
Burlington, Ontario, Kanada
- 1245.25.20042 Boehringer Ingelheim Investigational Site
-
Newmarket, Ontario, Kanada
- 1245.25.20009 Boehringer Ingelheim Investigational Site
-
Niagara Falls, Ontario, Kanada
- 1245.25.20044 Boehringer Ingelheim Investigational Site
-
Ottawa, Ontario, Kanada
- 1245.25.20013 Boehringer Ingelheim Investigational Site
-
Toronto, Ontario, Kanada
- 1245.25.20049 Boehringer Ingelheim Investigational Site
-
-
Quebec
-
Gatineau, Quebec, Kanada
- 1245.25.20050 Boehringer Ingelheim Investigational Site
-
Longueuil, Quebec, Kanada
- 1245.25.20043 Boehringer Ingelheim Investigational Site
-
Longueuil, Quebec, Kanada
- 1245.25.20046 Boehringer Ingelheim Investigational Site
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada
- 1245.25.20041 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Busan, Korea, Republiken av
- 1245.25.82030 Boehringer Ingelheim Investigational Site
-
Daegu, Korea, Republiken av
- 1245.25.82018 Boehringer Ingelheim Investigational Site
-
Daejeon, Korea, Republiken av
- 1245.25.82021 Boehringer Ingelheim Investigational Site
-
Daejoen, Korea, Republiken av
- 1245.25.82031 Boehringer Ingelheim Investigational Site
-
Goyang, Korea, Republiken av
- 1245.25.82027 Boehringer Ingelheim Investigational Site
-
Gwangju, Korea, Republiken av
- 1245.25.82022 Boehringer Ingelheim Investigational Site
-
Incheon, Korea, Republiken av
- 1245.25.82029 Boehringer Ingelheim Investigational Site
-
Pusan, Korea, Republiken av
- 1245.25.82017 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republiken av
- 1245.25.82015 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republiken av
- 1245.25.82016 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republiken av
- 1245.25.82019 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republiken av
- 1245.25.82020 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republiken av
- 1245.25.82023 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republiken av
- 1245.25.82024 Boehringer Ingelheim Investigational Site
-
Seoul, Korea, Republiken av
- 1245.25.82025 Boehringer Ingelheim Investigational Site
-
Suwon, Korea, Republiken av
- 1245.25.82026 Boehringer Ingelheim Investigational Site
-
Wonju, Korea, Republiken av
- 1245.25.82028 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Karlovac, Kroatien
- 1245.25.71005 Boehringer Ingelheim Investigational Site
-
Krapinske Toplice, Kroatien
- 1245.25.71001 Boehringer Ingelheim Investigational Site
-
Osijek, Kroatien
- 1245.25.71006 Boehringer Ingelheim Investigational Site
-
Rijeka, Kroatien
- 1245.25.71003 Boehringer Ingelheim Investigational Site
-
Zagreb, Kroatien
- 1245.25.71002 Boehringer Ingelheim Investigational Site
-
Zagreb, Kroatien
- 1245.25.71004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Johor Bahru, Malaysia
- 1245.25.60019 Boehringer Ingelheim Investigational Site
-
Kedah, Malaysia
- 1245.25.60020 Boehringer Ingelheim Investigational Site
-
Kelantan, Malaysia
- 1245.25.60013 Boehringer Ingelheim Investigational Site
-
Kota Kinabalu, Malaysia
- 1245.25.60015 Boehringer Ingelheim Investigational Site
-
Kuala Lumpur, Malaysia
- 1245.25.60012 Boehringer Ingelheim Investigational Site
-
Kuala Lumpur, Malaysia
- 1245.25.60017 Boehringer Ingelheim Investigational Site
-
Pahang, Malaysia
- 1245.25.60004 Boehringer Ingelheim Investigational Site
-
Selangor, Malaysia
- 1245.25.60016 Boehringer Ingelheim Investigational Site
-
Selangor, Malaysia
- 1245.25.60021 Boehringer Ingelheim Investigational Site
-
Selangor Darul Ehsan, Malaysia
- 1245.25.60018 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Colonia Americana, Mexiko
- 1245.25.52009 Boehringer Ingelheim Investigational Site
-
Distrito Federal, Mexiko
- 1245.25.52007 Boehringer Ingelheim Investigational Site
-
Ladron de Guevara, Mexiko
- 1245.25.52013 Boehringer Ingelheim Investigational Site
-
Los Robles, Mexiko
- 1245.25.52010 Boehringer Ingelheim Investigational Site
-
Monterrey, Mexiko
- 1245.25.52001 Boehringer Ingelheim Investigational Site
-
Reforma Social, Mexiko
- 1245.25.52011 Boehringer Ingelheim Investigational Site
-
San Lucas tepetlcalco, Mexiko
- 1245.25.52012 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amersfoort, Nederländerna
- 1245.25.31015 Boehringer Ingelheim Investigational Site
-
Apeldoorn, Nederländerna
- 1245.25.31013 Boehringer Ingelheim Investigational Site
-
Baarle - Nassau, Nederländerna
- 1245.25.31036 Boehringer Ingelheim Investigational Site
-
Delft, Nederländerna
- 1245.25.31032 Boehringer Ingelheim Investigational Site
-
Den Helder, Nederländerna
- 1245.25.31026 Boehringer Ingelheim Investigational Site
-
Geleen, Nederländerna
- 1245.25.31012 Boehringer Ingelheim Investigational Site
-
Hardenberg, Nederländerna
- 1245.25.31017 Boehringer Ingelheim Investigational Site
-
Heerlen, Nederländerna
- 1245.25.31035 Boehringer Ingelheim Investigational Site
-
Hoogeveen, Nederländerna
- 1245.25.31011 Boehringer Ingelheim Investigational Site
-
Hoogezand, Nederländerna
- 1245.25.31029 Boehringer Ingelheim Investigational Site
-
Hoogwoud, Nederländerna
- 1245.25.31023 Boehringer Ingelheim Investigational Site
-
Maastricht, Nederländerna
- 1245.25.31009 Boehringer Ingelheim Investigational Site
-
Meppel, Nederländerna
- 1245.25.31031 Boehringer Ingelheim Investigational Site
-
Nijverdal, Nederländerna
- 1245.25.31024 Boehringer Ingelheim Investigational Site
-
Rotterdam, Nederländerna
- 1245.25.31014 Boehringer Ingelheim Investigational Site
-
Rotterdam, Nederländerna
- 1245.25.31033 Boehringer Ingelheim Investigational Site
-
Schiedam, Nederländerna
- 1245.25.31030 Boehringer Ingelheim Investigational Site
-
Utrecht, Nederländerna
- 1245.25.31002 Boehringer Ingelheim Investigational Site
-
Wildervank, Nederländerna
- 1245.25.31028 Boehringer Ingelheim Investigational Site
-
Zutphen, Nederländerna
- 1245.25.31034 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Fornebu, Norge
- 1245.25.47002 Boehringer Ingelheim Investigational Site
-
Gjøvik, Norge
- 1245.25.47004 Boehringer Ingelheim Investigational Site
-
Kløfta, Norge
- 1245.25.47009 Boehringer Ingelheim Investigational Site
-
Kongsvinger, Norge
- 1245.25.47008 Boehringer Ingelheim Investigational Site
-
Oslo, Norge
- 1245.25.47001 Boehringer Ingelheim Investigational Site
-
Oslo, Norge
- 1245.25.47006 Boehringer Ingelheim Investigational Site
-
Trondheim, Norge
- 1245.25.47007 Boehringer Ingelheim Investigational Site
-
Tynset, Norge
- 1245.25.47005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Christchurch, Nya Zeeland
- 1245.25.64004 Boehringer Ingelheim Investigational Site
-
Grafton / Auckland, Nya Zeeland
- 1245.25.64001 Boehringer Ingelheim Investigational Site
-
Wellington, Nya Zeeland
- 1245.25.64003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Arequipa, Peru
- 1245.25.51001 Boehringer Ingelheim Investigational Site
-
Arequipa, Peru
- 1245.25.51008 Boehringer Ingelheim Investigational Site
-
Bellavista, Peru
- 1245.25.51002 Boehringer Ingelheim Investigational Site
-
El Agustino, Peru
- 1245.25.51004 Boehringer Ingelheim Investigational Site
-
Ica, Peru
- 1245.25.51006 Boehringer Ingelheim Investigational Site
-
Jesus Maria, Peru
- 1245.25.51003 Boehringer Ingelheim Investigational Site
-
Lima, Peru
- 1245.25.51007 Boehringer Ingelheim Investigational Site
-
Lima, Peru
- 1245.25.51009 Boehringer Ingelheim Investigational Site
-
Lima, Peru
- 1245.25.51010 Boehringer Ingelheim Investigational Site
-
Lima, Peru
- 1245.25.51011 Boehringer Ingelheim Investigational Site
-
Miraflores, Peru
- 1245.25.51005 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Gdansk, Polen
- 1245.25.48013 Boehringer Ingelheim Investigational Site
-
Lodz, Polen
- 1245.25.48004 Boehringer Ingelheim Investigational Site
-
Lodz, Polen
- 1245.25.48009 Boehringer Ingelheim Investigational Site
-
Lodz, Polen
- 1245.25.48010 Boehringer Ingelheim Investigational Site
-
Lublin, Polen
- 1245.25.48001 Boehringer Ingelheim Investigational Site
-
Oswiecim, Polen
- 1245.25.48014 Boehringer Ingelheim Investigational Site
-
Poznan, Polen
- 1245.25.48002 Boehringer Ingelheim Investigational Site
-
Pulawy, Polen
- 1245.25.48008 Boehringer Ingelheim Investigational Site
-
Ruda Slaska, Polen
- 1245.25.48007 Boehringer Ingelheim Investigational Site
-
Torun, Polen
- 1245.25.48005 Boehringer Ingelheim Investigational Site
-
Torun, Polen
- 1245.25.48011 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Amadora, Portugal
- 1245.25.35006 Boehringer Ingelheim Investigational Site
-
Coimbra, Portugal
- 1245.25.35004 Boehringer Ingelheim Investigational Site
-
Faro, Portugal
- 1245.25.35018 Boehringer Ingelheim Investigational Site
-
Funchal, Portugal
- 1245.25.35021 Boehringer Ingelheim Investigational Site
-
Leiria, Portugal
- 1245.25.35008 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugal
- 1245.25.35001 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugal
- 1245.25.35002 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugal
- 1245.25.35015 Boehringer Ingelheim Investigational Site
-
Lisboa, Portugal
- 1245.25.35017 Boehringer Ingelheim Investigational Site
-
Porto, Portugal
- 1245.25.35011 Boehringer Ingelheim Investigational Site
-
Santiago do Cacém, Portugal
- 1245.25.35005 Boehringer Ingelheim Investigational Site
-
Torres Novas, Portugal
- 1245.25.35020 Boehringer Ingelheim Investigational Site
-
Viana do Castelo, Portugal
- 1245.25.35014 Boehringer Ingelheim Investigational Site
-
Vila Nova de Gaia, Portugal
- 1245.25.35019 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Alba Iulia, Rumänien
- 1245.25.40008 Boehringer Ingelheim Investigational Site
-
Baia Mare Maramures, Rumänien
- 1245.25.40011 Boehringer Ingelheim Investigational Site
-
Bucharest, Rumänien
- 1245.25.40003 Boehringer Ingelheim Investigational Site
-
Bucharest, Rumänien
- 1245.25.40007 Boehringer Ingelheim Investigational Site
-
Constanta, Rumänien
- 1245.25.40005 Boehringer Ingelheim Investigational Site
-
Craiova, Rumänien
- 1245.25.40002 Boehringer Ingelheim Investigational Site
-
Craiova, Rumänien
- 1245.25.40006 Boehringer Ingelheim Investigational Site
-
Oradea, Rumänien
- 1245.25.40009 Boehringer Ingelheim Investigational Site
-
Targu-Mures, Rumänien
- 1245.25.40010 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Barnaul, Ryska Federationen
- 1245.25.70019 Boehringer Ingelheim Investigational Site
-
Kemerovo, Ryska Federationen
- 1245.25.70015 Boehringer Ingelheim Investigational Site
-
Kemerovo, Ryska Federationen
- 1245.25.70020 Boehringer Ingelheim Investigational Site
-
Moscow, Ryska Federationen
- 1245.25.70003 Boehringer Ingelheim Investigational Site
-
Moscow, Ryska Federationen
- 1245.25.70009 Boehringer Ingelheim Investigational Site
-
Moscow, Ryska Federationen
- 1245.25.70011 Boehringer Ingelheim Investigational Site
-
Moscow, Ryska Federationen
- 1245.25.70016 Boehringer Ingelheim Investigational Site
-
Moscow, Ryska Federationen
- 1245.25.70021 Boehringer Ingelheim Investigational Site
-
Moscow, Ryska Federationen
- 1245.25.70022 Boehringer Ingelheim Investigational Site
-
Novosibirsk, Ryska Federationen
- 1245.25.70014 Boehringer Ingelheim Investigational Site
-
Novosibirsk, Ryska Federationen
- 1245.25.70018 Boehringer Ingelheim Investigational Site
-
Novosibirsk, Ryska Federationen
- 1245.25.70024 Boehringer Ingelheim Investigational Site
-
Novosibirsk, Ryska Federationen
- 1245.25.70028 Boehringer Ingelheim Investigational Site
-
Saint Petersburg, Ryska Federationen
- 1245.25.70005 Boehringer Ingelheim Investigational Site
-
Saint Petersburg, Ryska Federationen
- 1245.25.70025 Boehringer Ingelheim Investigational Site
-
Saint Petersburg, Ryska Federationen
- 1245.25.70026 Boehringer Ingelheim Investigational Site
-
Saint Petersburg, Ryska Federationen
- 1245.25.70027 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Ryska Federationen
- 1245.25.70001 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Ryska Federationen
- 1245.25.70004 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Ryska Federationen
- 1245.25.70006 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Ryska Federationen
- 1245.25.70013 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Ryska Federationen
- 1245.25.70017 Boehringer Ingelheim Investigational Site
-
St. Petersburg, Ryska Federationen
- 1245.25.70023 Boehringer Ingelheim Investigational Site
-
Vsevolozhsk, Ryska Federationen
- 1245.25.70002 Boehringer Ingelheim Investigational Site
-
Yaroslavl, Ryska Federationen
- 1245.25.70029 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Singapore, Singapore
- 1245.25.65001 Boehringer Ingelheim Investigational Site
-
Singapore, Singapore
- 1245.25.65003 Boehringer Ingelheim Investigational Site
-
Singapore, Singapore
- 1245.25.65004 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Alcorcon (Madrid), Spanien
- 1245.25.34025 Boehringer Ingelheim Investigational Site
-
Alicante, Spanien
- 1245.25.34048 Boehringer Ingelheim Investigational Site
-
Alzira, Spanien
- 1245.25.34050 Boehringer Ingelheim Investigational Site
-
Avila, Spanien
- 1245.25.34039 Boehringer Ingelheim Investigational Site
-
Badía del Vallès - Barcelona, Spanien
- 1245.25.34040 Boehringer Ingelheim Investigational Site
-
Barcelona, Spanien
- 1245.25.34029 Boehringer Ingelheim Investigational Site
-
Barcelona, Spanien
- 1245.25.34030 Boehringer Ingelheim Investigational Site
-
Barcelona, Spanien
- 1245.25.34049 Boehringer Ingelheim Investigational Site
-
Granada, Spanien
- 1245.25.34031 Boehringer Ingelheim Investigational Site
-
Leganes (Madrid), Spanien
- 1245.25.34024 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1245.25.34013 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1245.25.34023 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1245.25.34026 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1245.25.34028 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1245.25.34033 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1245.25.34036 Boehringer Ingelheim Investigational Site
-
Madrid, Spanien
- 1245.25.34038 Boehringer Ingelheim Investigational Site
-
Mahadahonda (Madrid), Spanien
- 1245.25.34022 Boehringer Ingelheim Investigational Site
-
Palma de Mallorca, Spanien
- 1245.25.34047 Boehringer Ingelheim Investigational Site
-
Sabadell (Barcelona), Spanien
- 1245.25.34034 Boehringer Ingelheim Investigational Site
-
Salamanca, Spanien
- 1245.25.34027 Boehringer Ingelheim Investigational Site
-
Santa Cruz de Tenerife, Spanien
- 1245.25.34037 Boehringer Ingelheim Investigational Site
-
Segovia, Spanien
- 1245.25.34046 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Colombo, Sri Lanka
- 1245.25.94002 Boehringer Ingelheim Investigational Site
-
Kalubowila, Sri Lanka
- 1245.25.94005 Boehringer Ingelheim Investigational Site
-
Kandy, Sri Lanka
- 1245.25.94004 Boehringer Ingelheim Investigational Site
-
Kandy, Sri Lanka
- 1245.25.94006 Boehringer Ingelheim Investigational Site
-
Nugegoda, Sri Lanka
- 1245.25.94001 Boehringer Ingelheim Investigational Site
-
Ragama, Sri Lanka
- 1245.25.94003 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Airdrie, Storbritannien
- 1245.25.44045 Boehringer Ingelheim Investigational Site
-
Ashford, Storbritannien
- 1245.25.44020 Boehringer Ingelheim Investigational Site
-
Blackpool, Storbritannien
- 1245.25.44013 Boehringer Ingelheim Investigational Site
-
Bolton, Storbritannien
- 1245.25.44014 Boehringer Ingelheim Investigational Site
-
Bradford on Avon, Storbritannien
- 1245.25.44021 Boehringer Ingelheim Investigational Site
-
Dumfries, Storbritannien
- 1245.25.44002 Boehringer Ingelheim Investigational Site
-
Dundee, Storbritannien
- 1245.25.44009 Boehringer Ingelheim Investigational Site
-
Edinburgh, Storbritannien
- 1245.25.44005 Boehringer Ingelheim Investigational Site
-
Fowey, Storbritannien
- 1245.25.44004 Boehringer Ingelheim Investigational Site
-
Frome, Storbritannien
- 1245.25.44001 Boehringer Ingelheim Investigational Site
-
Inverness, Storbritannien
- 1245.25.44003 Boehringer Ingelheim Investigational Site
-
Wishaw, Storbritannien
- 1245.25.44044 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Alberton, Sydafrika
- 1245.25.76007 Boehringer Ingelheim Investigational Site
-
Bellville, Sydafrika
- 1245.25.76002 Boehringer Ingelheim Investigational Site
-
Bloemfontein, Sydafrika
- 1245.25.76009 Boehringer Ingelheim Investigational Site
-
Cape Town, Sydafrika
- 1245.25.76014 Boehringer Ingelheim Investigational Site
-
Cape Town, Sydafrika
- 1245.25.76020 Boehringer Ingelheim Investigational Site
-
Chatsworth Unit 10, Sydafrika
- 1245.25.76022 Boehringer Ingelheim Investigational Site
-
Durban, Sydafrika
- 1245.25.76013 Boehringer Ingelheim Investigational Site
-
Durban, Sydafrika
- 1245.25.76016 Boehringer Ingelheim Investigational Site
-
Durban, Sydafrika
- 1245.25.76019 Boehringer Ingelheim Investigational Site
-
Goodwood, Sydafrika
- 1245.25.76003 Boehringer Ingelheim Investigational Site
-
Houghton, Sydafrika
- 1245.25.76001 Boehringer Ingelheim Investigational Site
-
Kempton Park, Sydafrika
- 1245.25.76021 Boehringer Ingelheim Investigational Site
-
Krugersdorp, Sydafrika
- 1245.25.76017 Boehringer Ingelheim Investigational Site
-
Newtown, Sydafrika
- 1245.25.76004 Boehringer Ingelheim Investigational Site
-
Paarl, Sydafrika
- 1245.25.76006 Boehringer Ingelheim Investigational Site
-
Parow, Sydafrika
- 1245.25.76005 Boehringer Ingelheim Investigational Site
-
Port Elizabeth, Sydafrika
- 1245.25.76018 Boehringer Ingelheim Investigational Site
-
Somerset West, Sydafrika
- 1245.25.76015 Boehringer Ingelheim Investigational Site
-
Sydenham, Sydafrika
- 1245.25.76012 Boehringer Ingelheim Investigational Site
-
Tongaat, Sydafrika
- 1245.25.76008 Boehringer Ingelheim Investigational Site
-
Worcester, Sydafrika
- 1245.25.76023 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Hualien, Taiwan
- 1245.25.88022 Boehringer Ingelheim Investigational Site
-
Kaohsiung, Taiwan
- 1245.25.88010 Boehringer Ingelheim Investigational Site
-
Kaohsiung, Taiwan
- 1245.25.88019 Boehringer Ingelheim Investigational Site
-
Taichung, Taiwan
- 1245.25.88009 Boehringer Ingelheim Investigational Site
-
Taichung, Taiwan
- 1245.25.88020 Boehringer Ingelheim Investigational Site
-
Tainan, Taiwan
- 1245.25.88018 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwan
- 1245.25.88015 Boehringer Ingelheim Investigational Site
-
Taipei, Taiwan
- 1245.25.88016 Boehringer Ingelheim Investigational Site
-
Tamsui, Taipei county, Taiwan
- 1245.25.88023 Boehringer Ingelheim Investigational Site
-
Taoyuan, Taiwan
- 1245.25.88017 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Bangkok, Thailand
- 1245.25.66006 Boehringer Ingelheim Investigational Site
-
Bangkok, Thailand
- 1245.25.66007 Boehringer Ingelheim Investigational Site
-
Chiang Mai, Thailand
- 1245.25.66009 Boehringer Ingelheim Investigational Site
-
Muang District, Thailand
- 1245.25.66004 Boehringer Ingelheim Investigational Site
-
Nakhonratchasima, Thailand
- 1245.25.66010 Boehringer Ingelheim Investigational Site
-
Pathum Tani, Thailand
- 1245.25.66011 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Brno, Tjeckien
- 1245.25.42020 Boehringer Ingelheim Investigational Site
-
Jindrichuv Hradec, Tjeckien
- 1245.25.42018 Boehringer Ingelheim Investigational Site
-
Praha 3, Tjeckien
- 1245.25.42015 Boehringer Ingelheim Investigational Site
-
Usti nad Labem, Tjeckien
- 1245.25.42019 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Kharkiv, Ukraina
- 1245.25.75009 Boehringer Ingelheim Investigational Site
-
Kharkiv, Ukraina
- 1245.25.75011 Boehringer Ingelheim Investigational Site
-
Kharkov, Ukraina
- 1245.25.75001 Boehringer Ingelheim Investigational Site
-
Kharkov, Ukraina
- 1245.25.75008 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraina
- 1245.25.75007 Boehringer Ingelheim Investigational Site
-
Kiev, Ukraina
- 1245.25.75012 Boehringer Ingelheim Investigational Site
-
Odessa, Ukraina
- 1245.25.75010 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Budapest, Ungern
- 1245.25.36002 Boehringer Ingelheim Investigational Site
-
Budapest, Ungern
- 1245.25.36004 Boehringer Ingelheim Investigational Site
-
Budapest, Ungern
- 1245.25.36008 Boehringer Ingelheim Investigational Site
-
Dunaujvaros, Ungern
- 1245.25.36006 Boehringer Ingelheim Investigational Site
-
Gyula, Ungern
- 1245.25.36001 Boehringer Ingelheim Investigational Site
-
Kisvarda, Ungern
- 1245.25.36010 Boehringer Ingelheim Investigational Site
-
Szekszard, Ungern
- 1245.25.36003 Boehringer Ingelheim Investigational Site
-
Szikszo, Ungern
- 1245.25.36011 Boehringer Ingelheim Investigational Site
-
-
-
-
-
Feldkirch, Österrike
- 1245.25.43008 Boehringer Ingelheim Investigational Site
-
Graz, Österrike
- 1245.25.43006 Boehringer Ingelheim Investigational Site
-
Innsbruck, Österrike
- 1245.25.43016 Boehringer Ingelheim Investigational Site
-
Salzburg, Österrike
- 1245.25.43005 Boehringer Ingelheim Investigational Site
-
St. Stefan, Österrike
- 1245.25.43015 Boehringer Ingelheim Investigational Site
-
Wien, Österrike
- 1245.25.43001 Boehringer Ingelheim Investigational Site
-
Wien, Österrike
- 1245.25.43007 Boehringer Ingelheim Investigational Site
-
Wien, Österrike
- 1245.25.43009 Boehringer Ingelheim Investigational Site
-
Wien, Österrike
- 1245.25.43010 Boehringer Ingelheim Investigational Site
-
Wien, Österrike
- 1245.25.43013 Boehringer Ingelheim Investigational Site
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inklusionskriterier:
- Diagnos av typ 2 diabetes mellitus före informerat samtycke
- Manliga eller kvinnliga patienter på diet och träning som är drognaiva eller förbehandlade med någon bakgrundsterapi. Antidiabetisk behandling måste vara oförändrad i 12 veckor före randomisering.
- Glykosylerat hemoglobin (HbA1c) på >= 7,0% och <=10% för patienter i bakgrundsbehandling eller HbA1c >= 7,0% och <= 9,0% för läkemedelsnaiva patienter
- Ålder >= 18 år
- Body Mass Index <= 45 vid besök 1
- Undertecknat och daterat informerat samtycke
- Hög kardiovaskulär risk
Exklusions kriterier:
- Okontrollerad hyperglykemi med en glukosnivå >240 mg/dl (>13,3 mmol/L) efter en natts fasta under placebo-inkörning och bekräftad av en andra mätning (inte samma dag)
- Indikation på leversjukdom, definierad av serumnivåer av antingen alaninaminotransferas (ALT), aspartataminotransferas-ALAT eller alkaliskt fosfatas över 3 x den övre normalgränsen (ULN) bestämd vid screening och/eller inkörning.
- Planerad hjärtoperation eller angioplastik inom 3 månader
- Nedsatt njurfunktion, definierad som glomerulär filtreringshastighet <30 ml/min (svårt nedsatt njurfunktion, modifiering av dieten vid njursjukdom) under screening eller inkörning.
- Bariatrisk kirurgi under de senaste två åren och andra gastrointestinala operationer som inducerar kronisk malabsorption
- Bloddyskrasier eller andra störningar som orsakar hemolys eller instabila röda blodkroppar (t. malaria, babesios, hemolytisk anemi)
- Anamnes med cancer (förutom basalcellscancer) och/eller behandling för cancer under de senaste 5 åren
- Kontraindikationer mot bakgrundsbehandling enligt den lokala etiketten
- Behandling med läkemedel mot fetma (t.ex. sibutramin, orlistat) 3 månader före informerat samtycke eller någon annan behandling vid tidpunkten för screening (dvs. kirurgi, aggressiv diet, etc.) vilket leder till instabil kroppsvikt
- Aktuell behandling med systemiska steroider vid tidpunkten för informerat samtycke eller förändring i dos av sköldkörtelhormon inom 6 veckor före informerat samtycke eller någon annan okontrollerad endokrin störning förutom typ 2 diabetes mellitus
Premenopausala kvinnor (senaste menstruationen <+ 1 år före informerat samtycke) som:
- är ammande eller gravida eller
- är i fertil ålder och inte tillämpar en acceptabel preventivmetod, eller planerar inte att fortsätta använda denna metod under hela studien och går inte med på att underkasta sig periodiska graviditetstest under deltagande i försöket. Acceptabla metoder för preventivmedel inkluderar tubal ligering, transdermalt plåster, intrauterina enheter/system, orala, implanterbara eller injicerbara preventivmedel, sexuell avhållsamhet, dubbelbarriärmetod och vasektomerad partner
- Alkohol- eller drogmissbruk inom de tre månaderna före informerat samtycke som skulle störa deltagande i prövningen eller något pågående tillstånd som leder till minskad efterlevnad av studieprocedurer eller intag av studieläkemedel
- Deltagande i ytterligare en prövning med ett prövningsläkemedel inom 30 dagar före informerat samtycke
- Alla andra kliniska tillstånd som skulle äventyra patientsäkerheten när de deltar i denna kliniska prövning
- Akut kranskärlssyndrom, stroke eller TIA inom 2 månader före informerat samtycke
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
Placebotabletter som matchar BI 10773
|
Placebotabletter identiska med BI 10773
Placebotabletter identiska med BI 10773
|
|
Experimentell: BI 10773 låg dos
BI 10773 tabletter en gång dagligen
|
BI 10773 tabletter en gång dagligen
Placebotabletter identiska med BI 10773
|
|
Experimentell: BI 10773 hög dos
BI 10773 tabletter en gång dagligen
|
BI 10773 tabletter en gång dagligen
Placebotabletter identiska med BI 10773
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Tid till den första förekomsten av någon av följande bedömda komponenter i den primära sammansatta slutpunkten (3-punkts MACE): CV-död (inklusive dödlig stroke och dödlig hjärtinfarkt), icke-dödlig hjärtinfarkt (exklusive tyst hjärtinfarkt) och icke-dödlig stroke .
Tidsram: Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Tid till den första förekomsten av någon av följande bedömda komponenter i det primära sammansatta effektmåttet (3-punkts allvarliga kardiovaskulära händelser (MACE)): kardiovaskulär (CV) död (inklusive dödlig stroke och dödlig hjärtinfarkt (MI)), icke- fatal MI (exklusive tyst MI) och icke-dödlig stroke. Andel patienter med händelsen presenteras. |
Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Andel deltagare med sammansättningen av alla bedömda händelser (4-punkts MACE): CV-död (inklusive dödlig stroke och dödlig hjärtinfarkt), icke-dödlig hjärtinfarkt (exklusive tyst hjärtinfarkt), icke-dödlig stroke och sjukhusvistelse för instabil angina pectoris
Tidsram: Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Sammansättningen av alla bedömda händelser (4-punkts MACE): kardiovaskulär död (inklusive dödlig stroke och dödlig hjärtinfarkt), icke-dödlig hjärtinfarkt (exklusive tyst hjärtinfarkt), icke-dödlig stroke och sjukhusvistelse för instabil angina pectoris. nyckel sekundär endpoint för prövningen. Andel patienter med händelsen presenteras. |
Från randomisering till individuellt slut på observation, upp till 4,6 år
|
|
Andel deltagare med tyst MI
Tidsram: Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Tyst MI; definieras som närvaro i EKG av:
Det krävdes också att det inte hade förekommit någon bedömd och bekräftad händelse av vare sig akut hjärtinfarkt, sjukhusvistelse för instabil angina, koronar revaskulariseringsingrepp eller stenttrombos efter randomisering fram till och med datumet för den angivna EKG-mätningen. Andel patienter med händelsen presenteras. |
Från randomisering till individuellt slut på observation, upp till 4,6 år
|
|
Andel deltagare med hjärtsvikt som kräver sjukhusvistelse (bedömd)
Tidsram: Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Hjärtsvikt som kräver sjukhusvistelse (bedöms).
Andel patienter med händelsen presenteras.
|
Från randomisering till individuellt slut på observation, upp till 4,6 år
|
|
Andel deltagare med nystartad albuminuri
Tidsram: Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Nyuppstått albuminuri definieras som urinalbumin/kreatininförhållande (UACR) ≥30 mg/g. Andel patienter med händelsen presenteras. |
Från randomisering till individuellt slut på observation, upp till 4,6 år
|
|
Andel deltagare med nystartad makroalbuminuri
Tidsram: Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Nyuppkommen makroalbuminuri definierad som UACR >300 mg/g.
Andel patienter med händelsen presenteras.
|
Från randomisering till individuellt slut på observation, upp till 4,6 år
|
|
Andel deltagare med det sammansatta mikrovaskulära resultatet
Tidsram: Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Sammansatt mikrovaskulärt resultat definierat som:
|
Från randomisering till individuellt slut på observation, upp till 4,6 år
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Allmänna publikationer
- Tuttle KR, Levin A, Nangaku M, Kadowaki T, Agarwal R, Hauske SJ, Elsasser A, Ritter I, Steubl D, Wanner C, Wheeler DC. Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care. 2022 Jun 2;45(6):1445-1452. doi: 10.2337/dc21-2034.
- Wittbrodt ET, Eudicone JM, Bell KF, Enhoffer DM, Latham K, Green JB. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population. Am J Manag Care. 2018 Apr;24(8 Suppl):S138-S145.
- Kahl S, Ofstad AP, Zinman B, Wanner C, Schuler E, Sattar N, Inzucchi SE, Roden M. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes. Diabetes Obes Metab. 2022 Jun;24(6):1061-1071. doi: 10.1111/dom.14670. Epub 2022 Mar 8.
- Ruggenenti P, Kraus BJ, Inzucchi SE, Zinman B, Hantel S, Mattheus M, von Eynatten M, Remuzzi G, Koitka-Weber A, Wanner C. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine. 2021 Dec 24;43:101240. doi: 10.1016/j.eclinm.2021.101240. eCollection 2022 Jan.
- Reifsnider OS, Kansal AR, Wanner C, Pfarr E, Koitka-Weber A, Brand SB, Stargardter M, Wang C, Kuti E, Ustyugova A. Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial. Am J Kidney Dis. 2022 Jun;79(6):796-806. doi: 10.1053/j.ajkd.2021.09.014. Epub 2021 Nov 6.
- Ferreira JP, Inzucchi SE, Mattheus M, Meinicke T, Steubl D, Wanner C, Zinman B. Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2022 Jan;24(1):135-141. doi: 10.1111/dom.14559. Epub 2021 Oct 4.
- Vaduganathan M, Inzucchi SE, Sattar N, Fitchett DH, Ofstad AP, Brueckmann M, George JT, Verma S, Mattheus M, Wanner C, Zinman B, Butler J. Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. Diabetes Obes Metab. 2021 Dec;23(12):2775-2784. doi: 10.1111/dom.14535. Epub 2021 Oct 7.
- Sharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George JT, Hantel S, Desai N, Mentz RJ. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial. JACC Heart Fail. 2021 Aug;9(8):568-577. doi: 10.1016/j.jchf.2021.03.003.
- Cherney DZI, Dagogo-Jack S, McGuire DK, Cosentino F, Pratley R, Shih WJ, Frederich R, Maldonado M, Liu J, Wang S, Cannon CP; VERTIS CV Investigators. Kidney outcomes using a sustained >/=40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials. Clin Cardiol. 2021 Aug;44(8):1139-1143. doi: 10.1002/clc.23665. Epub 2021 Jun 15.
- Ferreira JP, Kraus BJ, Zwiener I, Lauer S, Zinman B, Fitchett DH, Koitka-Weber A, George JT, Ofstad AP, Wanner C, Zannad F. Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc. 2021 Apr 6;10(7):e020053. doi: 10.1161/JAHA.120.020053. Epub 2021 Mar 23.
- Ferreira JP, Verma S, Fitchett D, Ofstad AP, Lauer S, Zwiener I, George J, Wanner C, Zinman B, Inzucchi SE. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020 Nov 26;19(1):200. doi: 10.1186/s12933-020-01174-6.
- McGuire DK, Zinman B, Inzucchi SE, Wanner C, Fitchett D, Anker SD, Pocock S, Kaspers S, George JT, von Eynatten M, Johansen OE, Jamal W, Mattheus M, Elsasser U, Hantel S, Lund SS. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. Lancet Diabetes Endocrinol. 2020 Dec;8(12):949-959. doi: 10.1016/S2213-8587(20)30344-2.
- Ceriello A, Ofstad AP, Zwiener I, Kaspers S, George J, Nicolucci A. Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020 Oct 13;19(1):176. doi: 10.1186/s12933-020-01147-9.
- Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE; EMPA-REG OUTCOME Investigators. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2020 Dec;43(12):3007-3015. doi: 10.2337/dc20-1096. Epub 2020 Oct 1.
- Levin A, Perkovic V, Wheeler DC, Hantel S, George JT, von Eynatten M, Koitka-Weber A, Wanner C; EMPA-REG OUTCOME Investigators. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial. Clin J Am Soc Nephrol. 2020 Oct 7;15(10):1433-1444. doi: 10.2215/CJN.14901219. Epub 2020 Sep 29.
- Waijer SW, Xie D, Inzucchi SE, Zinman B, Koitka-Weber A, Mattheus M, von Eynatten M, Inker LA, Wanner C, Heerspink HJL. Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. J Am Heart Assoc. 2020 Sep 15;9(18):e016976. doi: 10.1161/JAHA.120.016976. Epub 2020 Sep 6.
- Bohm M, Fitchett D, Ofstad AP, Brueckmann M, Kaspers S, George JT, Zwiener I, Zinman B, Wanner C, Marx N, Mancia G, Anker SD, Mahfoud F. Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME. J Hypertens. 2020 Sep;38(9):1829-1840. doi: 10.1097/HJH.0000000000002492.
- Inzucchi SE, Khunti K, Fitchett DH, Wanner C, Mattheus M, George JT, Ofstad AP, Zinman B. Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. J Clin Endocrinol Metab. 2020 Sep 1;105(9):3025-35. doi: 10.1210/clinem/dgaa321.
- Ferreira JP, Fitchett D, Ofstad AP, Kraus BJ, Wanner C, Zwiener I, Zinman B, Lauer S, George JT, Rossignol P, Zannad F. Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial. Am J Hypertens. 2020 Dec 31;33(12):1092-1101. doi: 10.1093/ajh/hpaa073.
- Perkovic V, Koitka-Weber A, Cooper ME, Schernthaner G, Pfarr E, Woerle HJ, von Eynatten M, Wanner C. Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME(R) trial. Nephrol Dial Transplant. 2020 Dec 4;35(12):2103-2111. doi: 10.1093/ndt/gfz179.
- Kansal A, Reifsnider OS, Proskorovsky I, Zheng Y, Pfarr E, George JT, Kandaswamy P, Ruffolo A. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial. Diabet Med. 2019 Nov;36(11):1494-1502. doi: 10.1111/dme.14076. Epub 2019 Jul 23.
- Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C. Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure. Circ Heart Fail. 2019 Jun;12(6):e005875. doi: 10.1161/CIRCHEARTFAILURE.118.005875. Epub 2019 Jun 5.
- Verma S, Wanner C, Zwiener I, Ofstad AP, George JT, Fitchett D, Zinman B; EMPA-REG OUTCOME Investigators. Influence of Microvascular Disease on Cardiovascular Events in Type 2 Diabetes. J Am Coll Cardiol. 2019 Jun 4;73(21):2780-2782. doi: 10.1016/j.jacc.2019.03.002. Epub 2019 Mar 15. No abstract available.
- Januzzi J, Ferreira JP, Bohm M, Kaul S, Wanner C, Brueckmann M, Petrie MC, Ofstad AP, Zeller C, George J, Fitchett D, Zannad F. Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. Eur J Heart Fail. 2019 Mar;21(3):386-388. doi: 10.1002/ejhf.1419. Epub 2019 Feb 14. No abstract available.
- Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation. 2019 Mar 12;139(11):1384-1395. doi: 10.1161/CIRCULATIONAHA.118.037778.
- Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME(R) randomised trial. Diabetologia. 2018 Aug;61(8):1712-1723. doi: 10.1007/s00125-018-4644-9. Epub 2018 May 19.
- Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care. 2018 Feb;41(2):356-363. doi: 10.2337/dc17-1096. Epub 2017 Dec 4.
- Wanner C, Lachin JM, Inzucchi SE, Fitchett D, Mattheus M, George J, Woerle HJ, Broedl UC, von Eynatten M, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. Circulation. 2018 Jan 9;137(2):119-129. doi: 10.1161/CIRCULATIONAHA.117.028268. Epub 2017 Sep 13.
- Cherney DZI, Zinman B, Inzucchi SE, Koitka-Weber A, Mattheus M, von Eynatten M, Wanner C. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-621. doi: 10.1016/S2213-8587(17)30182-1. Epub 2017 Jun 27.
- Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, Mattheus M, Woerle HJ, Broedl UC, Johansen OE, Albers GW, Diener HC; EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. Stroke. 2017 May;48(5):1218-1225. doi: 10.1161/STROKEAHA.116.015756. Epub 2017 Apr 6.
- Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B; EMPA-REG OUTCOME Investigators. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016 Jul 28;375(4):323-34. doi: 10.1056/NEJMoa1515920. Epub 2016 Jun 14.
- Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
- Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol. 2014 Jun 19;13:102. doi: 10.1186/1475-2840-13-102.
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1245.25
- 2009-016178-33 (EudraCT-nummer: EudraCT)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .